Curated News
By: NewsRamp Editorial Staff
August 13, 2026
NeOnc's NEO100 Shows Promising Phase 2a Results; FDA Meeting Planned
TLDR
- NeOnc's NEO100 shows superior survival data, potentially outpacing current salvage therapies and improving competitive positioning in recurrent brain cancer.
- NEO100 met its primary endpoint in Phase 2a, with six-month PFS of 48.9% versus a 20% benchmark and median OS of 26.09 months, prompting a Type B FDA meeting.
- Positive trial results for NEO100 offer hope for recurrent brain cancer patients, with a well-tolerated treatment that may extend survival and improve quality of life.
- NEO100's trial data is a breakthrough, showing a 48.9% progression-free survival at six months, far exceeding the expected benchmark.
Impact - Why it Matters
This news matters because it offers hope for patients with recurrent brain cancer, a condition with limited treatment options and poor prognosis. The positive Phase 2a data for NEO100 suggests a potential new therapy that could significantly extend survival compared to current salvage treatments. For investors, it signals a potential advancement toward regulatory approval and commercialization, which could lead to substantial returns. Moreover, the progress of NEO212 and the expansion into other tumor types indicate a growing pipeline that could address multiple unmet medical needs, making NeOnc a key player in oncology innovation.
Summary
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has received an updated coverage note from Stonegate Capital Partners, highlighting significant progress in its clinical programs. The key development is the positive Phase 2a readout for NEO100, its lead drug candidate for recurrent brain cancer. The trial met its primary endpoint, demonstrating a six-month progression-free survival (PFS) rate of 48.9% using RANO 2.0 criteria and Kaplan-Meier estimation, compared to a pre-specified benchmark of 20% (p=0.0047). Median overall survival (OS) reached 26.09 months, with no major toxicities reported. This survival signal is particularly encouraging, as current salvage therapies for recurrent brain cancer typically offer only 6-9 months of survival benefit. The positive data positions NEO100 for a potential registrational program, with the company planning to request a Type B FDA meeting to discuss trial design and approval pathways.
Beyond NEO100, NeOnc's second asset, NEO212, has also gained regulatory momentum, receiving Phase 2 CMC clearance and FDA feedback indicating a potential accelerated approval pathway. The company is also expanding NEO100's development into meningioma and pediatric brain tumors, broadening its platform and increasing long-term optionality. Financially, R&D expenses increased to $2.6 million in Q2 2026 from $0.7 million year-over-year, reflecting the expanded development activities. The full announcement, including images and bios, is available at Stonegate's announcement. Key takeaways include the strengthened lead program, FDA alignment as a near-term catalyst, and the broadening investment case beyond a single asset. Stonegate Capital Partners, a capital markets advisory firm, provides this coverage, and the news was distributed by Reportable, Inc.
Source Statement
This curated news summary relied on content distributed by Reportable. Read the original source here, NeOnc's NEO100 Shows Promising Phase 2a Results; FDA Meeting Planned
